Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Increased dosing of blinatumomab in children and adolescents with Relapsed/Refractory B-lineage acute lymphoblastic leukemia – beneficial safety profile with 30µg/m²/day in a single center study

View Full Paper
Ask AI
Bookmark
Share

Authors

LGLiana GahleitnerCBChristian BraunCKChristoph Klein

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates that high-dose blinatumomab maintains safety profile while improving MRD responses in pediatric B-ALL.

Key Points

  • To evaluate the safety and efficacy of high-dose blinatumomab in pediatric patients with relapsed/refractory B-ALL.
  • Retrospective analysis of 18 pediatric patients
  • Comparison between standard-dose (15μg/m²/day) and high-dose (30μg/m²/day) blinatumomab
  • Assessment of adverse events and MRD before and after treatment
  • Cumulative therapeutic burden score evaluation
  • High-dose blinatumomab did not increase overall toxicity compared to standard dosing
  • Adverse events were similar between dosing groups
  • No grade ≥3 cytokine release syndrome observed in high-dose cycles
  • MRD reduction was comparable between standard-dose (32%) and high-dose (36%) cycles

Cite This Study

Gahleitner et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4d6https://doi.org/10.1182/blood-2025-6857
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  2. 2Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia2025 · 2 citations
  3. 3Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  4. 4Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 1 citations
  5. 5Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort2026